Tetrahydrobiopterin depletion and ubiquitylation of neuronal nitric oxide synthase.
Tetrahydrobiopterin is a necessary cofactor for the synthesis of nitric oxide by the hemeprotein enzyme, NO-synthase (NOS). It is widely thought that inadequate levels of tetrahydrobiopterin lead to tissue injury and organ dysfunction due, in part, to formation of superoxide from pterin-deficient NOS. In the course of studies on the ubiquitylation of neuronal NOS (nNOS), we have found that certain substrate analogs, such as N(G)-nitro-L-arginine, stabilize the dimeric form of nNOS and protect the enzyme from ubiquitylation. Since tetrahydrobiopterin is known to bind near heme and confers stability to the active dimeric structure of nNOS, we wondered if the loss of tetrahydrobiopterin could be an endogenous signal for nNOS ubiquitylation and degradation. We show here in HEK293 cells stably transfected with nNOS that depletion of tetrahydrobiopterin by treatment with 2,4-diamino-6-hydroxypyrimidine leads to destabilization of the dimeric form and enhances ubiquitylation of nNOS. Sepiapterin, a precursor to tetrahydrobiopterin in the salvage pathway, completely reverses the effect of 2,4-diamino-6-hydroxypyrimidine on nNOS ubiquitylation. Consistent with that found in cells, the in vitro ubiquitylation of nNOS by reticulocyte proteins decreases when tetrahydrobiopterin is present. Thus, inadequate amounts of tetrahydrobiopterin may lead to a sustained decrease in the steady state level of nNOS that is not readily reversed.
Kamada
Yasuhiko
Y
Department of Pharmacology, The University of Michigan Medical School, 1301 Medical Science Research Building III, Ann Arbor, MI 48109-0632, USA.
Jenkins
Gary J
GJ
Lau
Miranda
M
Dunbar
Anwar Y
AY
Lowe
Ezra R
ER
Osawa
Yoichi
Y
D001708:Biopterins / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D015153:Blotting, Western / Q000379:methods; D002460:Cell Line; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D019281:Dimerization; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005786:Gene Expression Regulation / Q000187:drug effects / Q000502:physiology; D006418:Heme / Q000378:metabolism; D006801:Humans; D007042:Hypoxanthines / Q000494:pharmacology; D047468:Immunoprecipitation / Q000379:methods; D007976:Leupeptins / Q000494:pharmacology; D052248:Nitric Oxide Synthase Type I / Q000737:chemistry / Q000378:metabolism*; D011622:Pterins / Q000494:pharmacology; D013997:Time Factors; D014452:Ubiquitins / Q000378:metabolism*
D004791:Enzyme Inhibitors; D007042:Hypoxanthines; D007976:Leupeptins; D011622:Pterins; D014452:Ubiquitins; D001708:Biopterins; D006418:Heme; C016727:sepiapterin; D052248:Nitric Oxide Synthase Type I; C017202:2,4-diaminohypoxanthine; C003402:sapropterin; C072553:benzyloxycarbonylleucyl-leucyl-leucine aldehyde